Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study

McGraw CA, Lublin FD (2013) Interferon beta and glatiramer acetate therapy. Neurotherapeutics : J Am Soc Experimental NeuroTherapeutics 10(1):2–18. https://doi.org/10.1007/s13311-012-0163-4 Pollack A (2013) 3rd Oral Drug to Treat MS Is Approved by the F.D.A. The New Your Times. [cited 2017 Jun 9]; Available from: http://www.nytimes.com/2013/03/28/business/3rd-oral-drug-to-treat-ms-is-approved-by-the-fda.html Fingolimod for multiple sclerosis (2012) Drug Ther Bull 50(2):18–20. https://doi.org/10.1136/dtb.2012.02.0086 Teriflunomide for multiple sclerosis (2014) Drug Ther Bull 52(7):81–84. https://doi.org/10.1136/dtb.2014.7.0267 Dimethyl fumarate for relapsing-remitting multiple sclerosis (2014) Drug Ther Bull 52(9):105–108. https://doi.org/10.1136/dtb.2014.9.0279 Wingerchuk DM, Weinshenker BG (2016) Disease modifying therapies for relapsing multiple sclerosis. BMJ (Clinical Res ed) 354:i3518. https://doi.org/10.1136/bmj.i3518 Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688. https://doi.org/10.1056/NEJMoa0706383 Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bjorck A, Axelsson M, Malmestrom C, Fink K, Lycke J, Svenningsson A, Piehl F (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79(6):950–958. https://doi.org/10.1002/ana.24651 Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, Rowland M, Schneider CK, Bloechl-Daum B (2011) Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov 10(7):495–506. https://doi.org/10.1038/nrd3501 Nordon C, Karcher H, Groenwold RH, Ankarfeldt MZ, Pichler F, Chevrou-Severac H, Rossignol M, Abbe A, Abenhaim L (2016) The “efficacy-effectiveness gap”: historical background and current conceptualization. Value Health : J Int Soc Pharmacoeconomics Outcomes Res 19(1):75–81. https://doi.org/10.1016/j.jval.2015.09.2938 Makady A, Ham RT, de Boer A, Hillege H, Klungel O, Goettsch W (2017) Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Health : J Int Soc Pharmacoeconomics Outcomes Res 20(4):520–532. https://doi.org/10.1016/j.jval.2016.12.003 TLV | Tandvårds- och läkemedelsförmånsverket | TLV [Internet]. Tlv.se. 2017 [cited 2017 Jun 9];Available from: https://www.tlv.se/ Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107. https://doi.org/10.1056/NEJMoa1114287 Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097. https://doi.org/10.1056/NEJMoa1206328 Wandell P, Carlsson AC, Wettermark B, Lord G, Cars T, Ljunggren G (2013) Most common diseases diagnosed in primary care in Stockholm, Sweden, in 2011. Fam Pract 30(5):506–513. https://doi.org/10.1093/fampra/cmt033 Cars T, Wettermark B, Lofberg R, Eriksson I, Sundstrom J, Lordal M (2016) Healthcare utilisation and drug treatment in a large cohort of patients with inflammatory bowel disease. J Crohn’s Colitis 10(5):556–565. https://doi.org/10.1093/ecco-jcc/jjv243 Forslund T, Wettermark B, Andersen M, Hjemdahl P (2017) Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology doi:https://doi.org/10.1093/europace/euw416 Åtgärdskoder (KVÅ) [Internet]. Socialstyrelsen.se. 2017 [cited 2017 Jun 9];Available from: http://www.socialstyrelsen.se/klassificeringochkoder/atgardskoderkva. http://www.socialstyrelsen.se/klassificeringochkoder/atgardskoderkva Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M (2007) The new Swedish prescribed drug register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726–735. https://doi.org/10.1002/pds.1294 Average Number of Drug Classes Used by Seniors on Public Drug Programs [Internet]. Indicatorlibrary.cihi.ca. 2017 [cited 2017 Jun 9];Available from: http://indicatorlibrary.cihi.ca/display/HSPIL/Average+Number+of+Drug+Classes+Used+by+Seniors+on+Public+Drug+Programs Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV (2010) Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 13(4):618–625. https://doi.org/10.3111/13696998.2010.523670 de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundstrom P, Svenningsson A (2016) Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology 87(2):141–147. https://doi.org/10.1212/wnl.0000000000002832 de Flon P, Laurell K, Soderstrom L, Gunnarsson M, Svenningsson A (2016) Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. Multiple sclerosis (Houndmills, Basingstoke, England):1352458516676643. doi:https://doi.org/10.1177/1352458516676643 Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A (2016) Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol 263(2):322–326. https://doi.org/10.1007/s00415-015-7979-x Salzer J, Svenningsson R, Alping P, Novakova L, Bjorck A, Fink K, Islam-Jakobsson P, Malmestrom C, Axelsson M, Vagberg M, Sundstrom P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074–2081. https://doi.org/10.1212/wnl.0000000000003331 Bergvall N, Lahoz R, Nazareth T, Korn JR (2014) Persistence with fingolimod versus dimethyl fumarate in patients with multiple sclerosis: retrospective analysis of us open-source pharmacy data. Value Health : J Int Soc Pharmacoeconomics Outcomes Res 17(7):A400–A401. https://doi.org/10.1016/j.jval.2014.08.912 Polson M, Lord T, Ko J, Evangelatos T, Herrera V (2016) Real world comparison of patient adherence and persistence to fingolimod vs. dimethyl fumarate (P3.101). Neurology 86 (16 Supplement). http://www.neurology.org/content/86/16_Supplement/P3.101 Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V (2017) Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Managed Care Specialty Pharmacy 23(8):844–852 Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D (2016) Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Multiple Sclerosis Related Disorders 10:44–52. https://doi.org/10.1016/j.msard.2016.08.002 Nazareth T, Friedman HS, Navaratnam P, Herriott DA, Ko JJ, Barr P, Sasane R (2016) Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review. BMC Neurol 16(1):187. https://doi.org/10.1186/s12883-016-0698-9 Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E (2017) Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Multiple Sclerosis Journal–Experimental, Translational and Clinical 3 (3):2055217317725102 Smoot K, Spinelli KJ, Stuchiner T, Lucas L, Chen C, Grote L, Baraban E, Kresa-Reahl K, Cohan S (2017) Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Multiple sclerosis (Houndmills, Basingstoke, England):1352458517709956. doi:https://doi.org/10.1177/1352458517709956 Individdata om rekvisitionsläkemedel: uppföljning, dokumentation och informatik. Nationella läkemedelsstrategin, område 6.4, slutrapport (2015). Sveriges Kommuner och Landsting, Stockholm Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48(8):999–1009 Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D (2003) Coding accuracy of administrative drug claims in the Ontario drug benefit database. Canadian J Clinical Pharmacology=J Canadien de Pharmacologie Clinique 10(2):67–71 Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323–337. https://doi.org/10.1016/j.jclinepi.2004.10.012